SNMMI Annual Meeting

June 22-June 25, 2019

Anaheim Convention Center Headquarter Hotel: Hilton Anaheim Anaheim, California

Thyroid Cancer Theranostics:
The Evolving Role for Nuclear Medicine in Clinical Genomics Paradigm

Session Organizers and Chairs:

Seza Gulec and Katherine Zukotynski

Course overview

This 8-hour session will provide an overview of theranostic concepts in thyroid cancer management. The first half of the session will concentrate on the genomics of thyroid cancer and discussion of the molecular testing. It will review the role of molecular testing in the differential diagnosis of thyroid nodules. The surgical treatment planning based on molecular pathology will be discussed. The second half of the session will focus on the molecular imaging. The rationale and clinical role for RAI imaging and treatment will be discussed in the context of the theranostic value of genomics and molecular profiling, with special reference to I-124 PET/CT imaging and dosimetry, as well as FDG PET/CT.

CME

The CME objectives are to discuss:

1) The basic principles of molecular testing for thyroid nodules

2) The role of molecular profiling as a theranostic tool for initial treatment of thyroid cancer

3) The role for postoperative RAI imaging and ablation in the context of the theranostic value of genomics and molecular profiling, with special reference to I-124 PET/CT imaging and dosimetry

CME need Justification:

Molecular profiling has made an impactful entry in the care of patients with thyroid nodules and thyroid cancer. RAI imaging and treatment principles are being redefined based on the new molecular pathology information. There is a need for reconfiguring the role for Nuclear Medicine in this changing paradigm.

Program

- Opening remarks: K. Zukotynski
- Molecular Diagnostics in Thyroid Nodules and Cancer Y. Nikiforov
- Genomic Theranostics of Thyroid Cancer for Surgery and Nuclear Medicine: S. Gulec
- Imaging for Thyroid Nodules K. Zukotynski
- Discussion
- Total Thyroidectomy-Complete Thyroidectomy S. Gulec
- The Art and Science of RAI ablation (Remnant/Occult Disease) M. Tulchinsky
- Discussion
- Lunch
- Pre-ablation RAI Imaging, I-131 and I-123 A. Avram
- PET/CT Imaging: FDG and I-124 D. Van Nostrand
- The Art and Science of RAI Therapy (Metastatic Disease) M. Tulchinsky
- Molecular Pathology of Thyroid Cancer Y. Nikiforov
- Targeted Therapy in Thyroid Cancer: Reversal of Fortune S. Gulec
- Panel Discussion K. Zukotynski
- Closing remarks: K. Zukotynski